Updated:
Maxpro Venture
Moses Chen leads Maxpro Venture, a biomedical VC with $1B+ AUM and 50+ exits across biopharma and medical devices.
Maxpro Venture
Maxpro Ventures is a biomedical technology investment firm identifying companies developing innovative drugs, devices, diagnostics, and services to fulfill people’s unmet medical needs and change their lives. At Maxpro Ventures, we create and discover value in the biomedical technology industry. We have been investing globally across the healthcare industry, from early-stage small companies to late-stage multinational corporations.
General information
Firm type
Venture Capital
Year founded
—
AUM
$1B+ (per firm website)
Location
Region
Asia
Country
Taiwan
City
Taipei
Corporate office
Taipei, Taiwan
Principals
Moses Chen
Managing Partner
Francis Chung
Managing Partner
Alex Chen
Managing Partner
Aimee Chen
Partner, General Manager China
Pin I Wu
Manager
Ying Chen
Assistant Vice President
Huei-Ling Liu
Manager
Sector focus
Frequently asked questions
Who runs investment decisions at Maxpro Venture?
Maxpro Venture lists three Managing Partners: Moses Chen (Ph.D.), Francis Chung (Ph.D., MBA), and Alex Chen (MS, MBA). The firm's website does not detail individual investment committee authorities, presenting the partnership as making collaborative decisions across their biomedical, investing, and operating expertise.
What investment stages does Maxpro Venture target?
Maxpro Venture pursues buyout, early-stage, and late-stage venture deals, covering the spectrum from company formation through pre-IPO expansion rounds. The firm states it provides both capital and strategic guidance, taking an active role in startup establishment, product design, and business development for its portfolio companies.
Is Maxpro Venture a single-family office or an independent fund?
Maxpro Venture operates as an Asset Manager, not a family office. It is structured as an independent venture capital and private equity firm, not as the private investment vehicle for a single family's wealth. Its funding sources and limited partners are not publicly disclosed.
Which sectors does Maxpro Venture focus on?
Maxpro Venture concentrates exclusively on biomedical technology. Its portfolio spans biologic drugs, cell therapy, small molecule drugs, and medical devices. The firm does not indicate investment activity outside life sciences, therapeutics, and medical technology.
What is Maxpro Venture's geographic reach?
The firm invests and maintains offices across Taiwan, China, Europe, and the United States, per its website. This trans-Pacific and trans-Atlantic footprint supports its strategy of identifying and scaling biomedical technology companies globally.
Does Maxpro Venture have any public portfolio company names?
No. The firm's website does not list any specific portfolio companies by name. It provides a general description of sectors but no individual company or deal-level disclosure, which limits public verification of its claimed $1B+ AUM and exit track record.
What is the wealth origin behind Maxpro Venture?
The firm does not disclose a founding wealth origin. Maxpro Venture presents itself as a partnership among career venture capitalists and biomedical experts, not as the investment arm of a single industrial or financial fortune.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: